ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CVG CSPC Pharmaceutical Group Limited

0.8306
-0.0344 (-3.98%)
19:51:41 - Realtime Data
Share Name Share Symbol Market Type
CSPC Pharmaceutical Group Limited TG:CVG Tradegate Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0344 -3.98% 0.8306 0.8004 0.8198 0.844 0.8002 0.8206 100,815 19:51:41

Convergys 1Q Net Falls 22% On Slump In Information Management

28/04/2009 2:07pm

Dow Jones News


CSPC Pharmaceutical (TG:CVG)
Historical Stock Chart


From Oct 2019 to Oct 2024

Click Here for more CSPC Pharmaceutical Charts.
   DOW JONES NEWSWIRES 
 

Convergys Corp. (CVG) said first-quarter net income fell 22% on a slump in sales at its information-management business.

In December, Moody's Investors Service cut Covergys' ratings to junk, saying its human-resources management business was weak and it needed to sign big contracts.

President and Chief Executive David Dougherty said the company's customer-management segment was a source of profitability. He added the company was expanding its delivery footprint.

The provider of integrated billing, employee care and customer-care services posted net income of $28 million, or 23 cents a share, from $35.9 million, or 28 cents a share, a year earlier. The previous year's results included $14.1 million in restructuring charges and $7.1 million in retirement-related expenses.

Revenue decreased 3% to $694.7 million.

Analysts surveyed by Thomson Reuters expected 20 cents a share in earnings on $695 million in revenue.

Gross margin rose to 36.2% from 234.1.

Revenue from the company's largest segment, customer management, rose 9% as operating margins rose to 7.8% from 4.6%. Sales at its information-management business fell 34% on project completions and expected client migrations in North America. Operating margins fell to 11.6% from 18.1% last year.

The company affirmed its full-year earnings guidance from January of 90 cents to $1.10 a share.

The stock closed Monday at $9.67 and wasn't active premarket. Convergys' stock price fell to an all-time low in November but has since doubled in value.

-By Joan E. Solsman and Kerry E. Grace, Dow Jones Newswires; 201-938-5500; joan.solsman@dowjones.com

 
 

1 Year CSPC Pharmaceutical Chart

1 Year CSPC Pharmaceutical Chart

1 Month CSPC Pharmaceutical Chart

1 Month CSPC Pharmaceutical Chart

Your Recent History

Delayed Upgrade Clock